The latest announcement is out from Telix Pharmaceuticals Ltd. ( (AU:TLX) ).
Telix Pharmaceuticals Limited has announced promising preliminary results from the Phase 2 IPAX-Linz study of TLX101, a glioma therapy candidate, in patients with recurrent high-grade glioma. The study showed that TLX101, in combination with external beam radiation therapy, was well tolerated and demonstrated encouraging efficacy, with a median overall survival of 12.4 months from treatment initiation. These findings suggest TLX101’s potential to improve outcomes for patients with high-grade glioma, supporting further research and higher therapeutic doses in future studies.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company is committed to addressing significant unmet medical needs in oncology and rare diseases, with a portfolio of clinical and commercial stage products.
YTD Price Performance: 15.55%
Average Trading Volume: 5,165
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.64B
See more data about TLX stock on TipRanks’ Stock Analysis page.